-
公开(公告)号：US20090191187A1
公开(公告)日：2009-07-30
申请号：US12370628
申请日：2009-02-13
申请人： Ilse Bartke , Francis Carr , Richard Anthony Chizzonite , Elsie M. Eugui , Georg Fertig , Anita Hamilton , Martin Lanzendoerfer , Petra Rueger , Ralf Schumacher , Theresa Patricia Truitt
发明人： Ilse Bartke , Francis Carr , Richard Anthony Chizzonite , Elsie M. Eugui , Georg Fertig , Anita Hamilton , Martin Lanzendoerfer , Petra Rueger , Ralf Schumacher , Theresa Patricia Truitt
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis.
摘要翻译： 本发明涉及抗白细胞介素-1受体（IL-1R）的抗体，其制备方法，含有所述抗体的药物组合物及其用途。 本发明的抗体特别可用于治疗各种炎性疾病，包括但不限于类风湿性关节炎。
-
公开(公告)号：US20050118169A1
公开(公告)日：2005-06-02
申请号：US10937596
申请日：2004-09-09
申请人： Ilse Bartke , Francis Carr , Richard Chizzonite , Elsie Eugui , Georg Fertig , Anita Hamilton , Martin Lanzendoerfer , Petra Rueger , Ralf Schumacher , Theresa Truitt
发明人： Ilse Bartke , Francis Carr , Richard Chizzonite , Elsie Eugui , Georg Fertig , Anita Hamilton , Martin Lanzendoerfer , Petra Rueger , Ralf Schumacher , Theresa Truitt
IPC分类号： A61K39/395 , C07H21/04 , C07K16/28 , C12N5/06 , C12N15/13
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis.
摘要翻译： 本发明涉及抗白细胞介素-1受体（IL-1R）的抗体，其制备方法，含有所述抗体的药物组合物及其用途。 本发明的抗体特别可用于治疗各种炎性疾病，包括但不限于类风湿性关节炎。
-
公开(公告)号：US06790852B2
公开(公告)日：2004-09-14
申请号：US10408539
申请日：2003-04-07
IPC分类号： A61K31506
CPC分类号： C07D403/04 , C07C45/511 , C07C45/673 , C07C45/71 , C07C47/565 , C07C47/575 , C07C69/708 , C07C303/28 , C07C315/02 , C07C319/14 , C07D405/14 , C07F7/1804 , C07F9/65583 , C07C317/24 , C07C323/22 , C07C323/52 , C07C323/62 , C07C309/66 , C07C309/73
摘要： The invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and related diseases.
摘要翻译： 本发明涉及式（I）化合物，其是用于治疗癌症和相关疾病的有价值的治疗剂。
-
公开(公告)号：US08883159B2
公开(公告)日：2014-11-11
申请号：US12868849
申请日：2010-08-26
申请人： Birgit Bossenmaier , Georg Fertig , Hans-Willi Krell , Reiner Lammers , Alexander Lifke , Gerhard Niederfellner
发明人： Birgit Bossenmaier , Georg Fertig , Hans-Willi Krell , Reiner Lammers , Alexander Lifke , Gerhard Niederfellner
IPC分类号： A61K39/395 , A61P35/04 , C07K16/30 , C07K16/28 , C12N15/13 , C12N15/85 , C12N5/10 , A61K39/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76
摘要： The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.
摘要翻译： 本发明涉及抗CDCP1与CUB4（沉积号DSM ACC2551）相同表位的抗体用于治疗癌症的抗体。
-
公开(公告)号：US07501451B2
公开(公告)日：2009-03-10
申请号：US11296162
申请日：2005-12-06
申请人： Georg Fertig , Frank Herting , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Michael Weidner
发明人： Georg Fertig , Frank Herting , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Michael Weidner
IPC分类号： A61K31/381 , C07D333/22
CPC分类号： C07D213/82 , C07C233/80 , C07C2601/02 , C07D333/38
摘要： Mono-acylated o-phenylendiamines derivatives of formula A: which are useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.
摘要翻译： 式A的单酰化邻苯二胺衍生物：其可用于治疗由组蛋白脱乙酰酶抑制如癌症介导的疾病。
-
公开(公告)号：US07098247B2
公开(公告)日：2006-08-29
申请号：US10732026
申请日：2003-12-10
申请人： Georg Fertig , Frank Herting , Matthias Koerner , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Michael Weidner
发明人： Georg Fertig , Frank Herting , Matthias Koerner , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Michael Weidner
IPC分类号： A61K31/16
CPC分类号： C07D213/82 , C07C237/42 , C07C275/24 , C07C2601/02 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07D333/38
摘要： The present invention describes compounds of the general formula I as well as processes for their manufacture, pharmaceutical compositions containing them and methods for using these compounds and pharmaceutical compositions as pharmaceutical agents. The compounds according to this invention show antiproliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion.
摘要翻译： 本发明描述了通式I的化合物及其制备方法，含有它们的药物组合物以及使用这些化合物和药物组合物作为药剂的方法。 根据本发明的化合物显示抗增殖和分化诱导活性，其导致抑制肿瘤细胞增殖，诱导凋亡和抑制侵袭。
-
公开(公告)号：US06946471B2
公开(公告)日：2005-09-20
申请号：US10848611
申请日：2004-05-18
IPC分类号： C07D317/22 , A61K31/505 , A61K31/506 , A61K31/5377 , A61P13/08 , A61P35/00 , A61P43/00 , C07B53/00 , C07C45/51 , C07C45/67 , C07C45/71 , C07C47/55 , C07C47/565 , C07C47/575 , C07C69/708 , C07C303/28 , C07C309/66 , C07C309/73 , C07C315/02 , C07C317/24 , C07C319/14 , C07C323/22 , C07C323/52 , C07C323/62 , C07C403/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07F7/18 , C07F9/6558
CPC分类号： C07D403/04 , C07C45/511 , C07C45/673 , C07C45/71 , C07C47/565 , C07C47/575 , C07C69/708 , C07C303/28 , C07C315/02 , C07C319/14 , C07D405/14 , C07F7/1804 , C07F9/65583 , C07C317/24 , C07C323/22 , C07C323/52 , C07C323/62 , C07C309/66 , C07C309/73
摘要： This invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and cancer related diseases.
摘要翻译： 本发明涉及式（I）化合物，其是用于治疗癌症和癌症相关疾病的有价值的治疗剂。
-
公开(公告)号：US08785153B2
公开(公告)日：2014-07-22
申请号：US13402399
申请日：2012-02-22
申请人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
发明人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
IPC分类号： C12P21/08
CPC分类号： C07K16/2866 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K2317/24 , C07K2317/30 , C07K2317/76 , C07K2317/92
摘要： An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
摘要翻译： 结合IL33R的抗体，其特征在于重链可变结构域包含SEQ ID NO：1的CDR3区，SEQ ID NO：2的CDR2区和SEQ ID NO：3的CDR1区，并且其中轻链可变区 结构域包含SEQ ID NO：4的CDR3区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR1区或嵌合，人源化或T细胞表位缺失的抗体变体具有治疗的有利性质 的炎性疾病。
-
9.发明申请COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR 审中-公开抗抑郁剂类型II抗CD20抗体的联合治疗公开(公告)号：US20110200598A1
公开(公告)日：2011-08-18
申请号：US13075946
申请日：2011-03-30
申请人： Georg Fertig , Thomas Friess , Christian Klein , Pablo Umana
发明人： Georg Fertig , Thomas Friess , Christian Klein , Pablo Umana
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/69 , A61K47/00 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/41 , A61K2300/00
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and a proteasome inhibitor. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and a proteasome inhibitor. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor.
摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是表达CD20的癌症的II型抗-CD20抗体和蛋白酶体抑制剂的组合疗法。 本发明的一个方面是包含II型抗CD20抗体和蛋白酶体抑制剂的组合物。 本发明的另一方面是包含II型抗CD20抗体和蛋白酶体抑制剂的试剂盒。 本发明的另一方面是治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同施用II型抗CD20抗体和蛋白酶体抑制剂。
-
10.发明授权公开(公告)号：US07759071B2
公开(公告)日：2010-07-20
申请号：US11738899
申请日：2007-04-23
申请人： Stefan Holdenrieder , Martin Busch , Heinz Bodenmueller , Georg Fertig , Andreas Schalhorn , Petra Stieber
发明人： Stefan Holdenrieder , Martin Busch , Heinz Bodenmueller , Georg Fertig , Andreas Schalhorn , Petra Stieber
IPC分类号： G01N33/53 , C12Q1/68 , C12P19/34 , A61K39/395 , C07H21/02
CPC分类号： G01N33/5091 , G01N33/5308 , G01N2800/52
摘要： The present invention concerns a method for the determination of apoptotic products in samples taken from patients in which apoptosis is induced as a result of disease or therapy, which is characterized in that the concentration of the apoptotic products in samples taken from patients is correlated with the effectiveness of the therapy and thus serves as a follow-up for the therapy. The present invention in particular concerns a method in which the concentration of nucleosomes is determined in serum samples of tumour patients in order to assess the effectiveness of tumour therapy. Furthermore the present invention also concerns the use of a method according to the invention to determine the effectiveness of therapy in tumour patients who are subjected to a radiotherapy or chemotherapy treatment as well as in patients after an acute ischaemic event or after hypothermia treatment.
摘要翻译： 本发明涉及一种用于测定来自患者的凋亡产物的方法，其中所述样品取自患有由疾病或治疗引起的细胞凋亡的患者，其特征在于，取自患者的样品中的凋亡产物的浓度与 治疗的有效性，从而作为治疗的后续行动。 本发明特别涉及一种方法，其中在肿瘤患者的血清样品中测定核小体的浓度，以评估肿瘤治疗的有效性。 此外，本发明还涉及根据本发明的方法用于确定经受放射治疗或化疗治疗的肿瘤患者以及急性缺血事件或低体温治疗后患者的治疗效果的用途。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.04 秒)
